Evaluating the Budget Impact on the Health Care System in England and Wales of RefluxStop As a Treatment for Refractory Gastroesophageal Reflux Disease (GORD)


Shore J1, Grodzicki L2, Harper S3, Mealing S3, Golam S4
1York Health Economics Consortium (YHEC), York, UK, 2York Health Economics Consortium (YHEC), York, NYK, UK, 3York Health Economics Consortium (YHEC), York, YOR, UK, 4Implantica, Zug, Switzerland


Gastroesophageal reflux disease (GORD) is a disease characterised by heartburn, chest pain, difficulty swallowing and regurgitation of food. Standard treatment is the prescription of a proton pump inhibitor (PPI). The treatment options for failed medical treatment include the Nissen fundoplication and LINX system reflux treatment. RefluxStop is an implantable single-use device implanted by using standard laparoscopic surgery. This abstract looks at the budget impact associated with introducing the RefluxStop procedure into the National Health Service (NHS) in England and Wales.


A five-year time horizon, one-year cycle length and the UK NHS perspective were used in the analysis. Estimates for the England and Wales population and population growth projections were obtained from the Office for National Statistics (ONS) database. GORD prevalence, incidence rate and the general population operative rate of laparoscopic anti-reflux surgery in the UK were taken from medical literature. The current market share of individuals requiring either of the two surgical options as well as the market share post RefluxStop launch were based on Implantica market research and assumptions. Unit costs were sourced from national databases and published literature. Extensive sensitivity analyses were undertaken around key model inputs.


The overall one-year, three-year and five-year financial impacts of introducing RefluxStop were £713,430, £2,122,955 and £3,039,561 per year, respectively, which corresponded to 0.39%, 1.14% and 1.68% increases per year in overall NHS expenditure for GORD treatment in England and Wales. The use of more optimistic and pessimistic market uptake rates (doubled and halved market uptake of RefluxStop) led to one-year increases in NHS expenditure of 0.79% and 0.20% and five-year increases of 3.36% and 0.84%, respectively.


The introduction of RefluxStop is likely to only have a marginal impact on England and Wales NHS budget.

Conference/Value in Health Info

2022-11, ISPOR Europe 2022, Vienna, Austria

Value in Health, Volume 25, Issue 12S (December 2022)




Economic Evaluation

Topic Subcategory

Budget Impact Analysis


No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now